Vironexis Biotherapeutics

About:

Vironexis has the potential to transform immunotherapy and the way cancer is treated in the future.

Website: https://vironexis.com

Twitter/X: vironexis

Top Investors: Capital Factory, Drive Capital, Moonshots Capital, Future Ventures

Description:

Vironexis will implement the cutting-edge technique of AAV-delivered T-cell immunotherapy.

Total Funding Amount:

$26M

Headquarters Location:

California, Kentucky, United States

Founded Date:

2021-01-01

Founders:

Brian Kaspar, Timothy P. Cripe

Number of Employees:

11-50

Last Funding Date:

2024-09-12

IPO Status:

Private

Industries: